Brokerage firm RBC Capital Downgrades its rating on LDR Holding Corp(NASDAQ:LDRH). The shares have been rated Sector Perform. Previously, the analysts had a Outperform rating on the shares. The rating by RBC Capital was issued on Jun 9, 2016.
In a different note, On Jun 8, 2016, Gabelli & Co. said it Downgrades its rating on LDR Holding Corp. The shares have been rated ‘Hold’ by the firm. Barclays said it Initiates Coverage on LDR Holding Corp, according to a research note issued on May 27, 2016. The shares have been rated ‘Overweight’ by the firm. Gabelli & Co said it Initiates Coverage on LDR Holding Corp, according to a research note issued on Apr 15, 2016. The shares have been rated ‘Buy’ by the firm.
LDR Holding Corp (LDRH) made into the market gainers list on Wednesdays trading session with the shares advancing 0.33% or 0.12 points. Due to strong positive momentum, the stock ended at $37.02, which is also near the day’s high of $37.77. The stock began the session at $37 and the volume stood at 21,90,670 shares. The 52-week high of the shares is $47.12 and the 52 week low is $16.33. The company has a current market capitalization of $1,082 M and it has 2,92,32,859 shares in outstanding.
LDR Holding Corp(LDRH) last announced its earnings results on May 10, 2016 for Fiscal Year 2016 and Q1.Company reported revenue of $42.39M. Analysts had an estimated revenue of $42.83M. Earnings per share were $-0.26. Analysts had estimated an EPS of $-0.23.
Several Insider Transactions has been reported to the SEC. On Apr 19, 2016, Patrick Richard (EVP, European Sales, Medical) sold 25,000 shares at $27.60 per share price.Also, On Mar 11, 2016, G. Joseph Ross (Exec VP Global Marketing) sold 17,613 shares at $23.07 per share price.On Nov 12, 2015, Robert Mcnamara (Chief Financial Officer) sold 19,373 shares at $26.15 per share price, according to the Form-4 filing with the securities and exchange commission.
LDR Holding Corporation is a global medical device company. The Company is focused on designing and commercializing surgical technologies for the treatment of patients suffering from spine disorders. The Company’s primary products are based on its VerteBRIDGE fusion and Mobi non-fusion platforms both of which are designed for applications in the cervical and lumbar spine. The Company’s VerteBRIDGE products are designed around its plating technology that enables surgeons to implant VerteBRIDGE devices with direct visualization of the disc and to affix the devices to the vertebrae from inside the spinal disc space. The Company’s Mobi non-fusion platform is highlighted by Mobi-C a cervical disc replacement device with a patented mobile bearing core that is designed to replicate the natural anatomical movement of the spine by facilitating independent bending and twisting similar to a healthy disc.